Combination Immunotherapy with Cytotoxic T-Lymphocyte-Associated Antigen-4 and Programmed Death Protein-1 Inhibitors Prevents Postoperative Breast Tumor Recurrence and Metastasis

doi:10.1158/1535-7163.MCT-19-0495

	Combination Immunotherapy with Cytotoxic T-Lymphocyte-Associated Antigen-4 and Programmed Death Protein-1 Inhibitors Prevents Postoperative Breast Tumor Recurrence and Metastasis
	Sun, Ting 1,2; Zhang, Wenjia 1,2; Li, Yuan 1; Jin, Zhengyu 1; Du, Yang2,3 ; Tian, Jie 2,3; Xue, Huadan 1
发表期刊	MOLECULAR CANCER THERAPEUTICS
ISSN	1535-7163
	2020-03-01
卷号	19 期号:3 页码:802-811
通讯作者	Du, Yang(yang.du@ia.ac.cn) ; Tian, Jie(jie.tian@ia.ac.cn) ; Xue, Huadan(bjdanna95@hotmail.com)
摘要	Postoperative tumor recurrence and metastasis remain an extreme challenge in breast cancer. Therapies that target cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1) have provided unprecedented clinical benefits in various types of cancer. The aim of this study was to determine whether the combination of anti-CTLA-4 and anti-PD-1 could prevent postoperative breast tumor recurrence and metastasis in breast tumor-bearing mice. 1'he results indicated that the combination of CTLA-4 and PD-1 inhibitors was more effective compared with single inhibitors for mammary tumor growth and prevention of postsurgical tumor recurrence and pulmonary metastasis (P < 0.05), which resulted in prolonged survival (P < 0.05). Analysis of the underlying mechanism revealed that anti-CTLA-4 and anti-PD-1 in combination synergistically promoted the infiltration of CD8+ and CD4+ T cells into tumors (P < 0.05 vs. single inhibitors), thus boosting the antitumor immune responses. In summary, our results revealed that combination immunotherapy with anti-CTLA-4 and anti-PD-1 may present a new, promising regimen to inhibit postoperative breast cancer relapse and lung metastasis and improve patient outcomes, which warrants further investigation in clinical settings.
DOI	10.1158/1535-7163.MCT-19-0495
关键词[WOS]	IMMUNE CHECKPOINT INHIBITORS ; CARCINOMA IN-SITU ; INFILTRATING LYMPHOCYTES ; COMBINED NIVOLUMAB ; ADVERSE EVENTS ; PD-1 BLOCKADE ; CANCER ; SURVIVAL ; PEMBROLIZUMAB ; IPILIMUMAB
收录类别	SCI
语种	英语
资助项目	National Key Research and Development Plan of China[2017YFA0205200] ; National Natural Science Foundation of China[81371608] ; National Natural Science Foundation of China[81871514] ; National Natural Science Foundation of China[81470083] ; National Natural Science Foundation of China[81227901] ; Beijing Natural Science Foundation[7172170] ; National Public Welfare Basic Scientific Research Project[2017PT32004] ; Chinese Academy of Medical Sciences Students' Innovation Foundation[1007-1002-1-12] ; National Key Research and Development Plan of China[2017YFA0205200] ; National Natural Science Foundation of China[81371608] ; National Natural Science Foundation of China[81871514] ; National Natural Science Foundation of China[81470083] ; National Natural Science Foundation of China[81227901] ; Beijing Natural Science Foundation[7172170] ; National Public Welfare Basic Scientific Research Project[2017PT32004] ; Chinese Academy of Medical Sciences Students' Innovation Foundation[1007-1002-1-12]
项目资助者	National Key Research and Development Plan of China ; National Natural Science Foundation of China ; Beijing Natural Science Foundation ; National Public Welfare Basic Scientific Research Project ; Chinese Academy of Medical Sciences Students' Innovation Foundation
WOS研究方向	Oncology
WOS类目	Oncology
WOS记录号	WOS:000518190200007
出版者	AMER ASSOC CANCER RESEARCH
七大方向——子方向分类	其他
引用统计	被引频次：15[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	http://ir.ia.ac.cn/handle/173211/38432
专题	中国科学院分子影像重点实验室
通讯作者	Du, Yang; Tian, Jie; Xue, Huadan
作者单位	1.Peking Union Med Coll & Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Radiol, Beijing, Peoples R China 2.Chinese Acad Sci, Inst Automat, CAS Key Lab Mol Imaging, State Key Lab Management & Control Complex Syst, Beijing, Peoples R China 3.Univ Chinese Acad Sci, Beijing, Peoples R China
第一作者单位	中国科学院自动化研究所
通讯作者单位	中国科学院自动化研究所
推荐引用方式 GB/T 7714	Sun, Ting,Zhang, Wenjia,Li, Yuan,et al. Combination Immunotherapy with Cytotoxic T-Lymphocyte-Associated Antigen-4 and Programmed Death Protein-1 Inhibitors Prevents Postoperative Breast Tumor Recurrence and Metastasis[J]. MOLECULAR CANCER THERAPEUTICS,2020,19(3):802-811.
APA	Sun, Ting.,Zhang, Wenjia.,Li, Yuan.,Jin, Zhengyu.,Du, Yang.,...&Xue, Huadan.(2020).Combination Immunotherapy with Cytotoxic T-Lymphocyte-Associated Antigen-4 and Programmed Death Protein-1 Inhibitors Prevents Postoperative Breast Tumor Recurrence and Metastasis.MOLECULAR CANCER THERAPEUTICS,19(3),802-811.
MLA	Sun, Ting,et al."Combination Immunotherapy with Cytotoxic T-Lymphocyte-Associated Antigen-4 and Programmed Death Protein-1 Inhibitors Prevents Postoperative Breast Tumor Recurrence and Metastasis".MOLECULAR CANCER THERAPEUTICS 19.3(2020):802-811.